International staging system and metaphase cytogenetic abnormalities in the era of gene expression profiling data in multiple myeloma treated with total therapy 2 and 3 protocols
Open Access
- 13 October 2010
- Vol. 117 (5), 1001-1009
- https://doi.org/10.1002/cncr.25535
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- International Myeloma Working Group molecular classification of multiple myeloma: spotlight reviewLeukemia, 2009
- Gene expression profiling of plasma cells at myeloma relapse from tandem transplantation trial Total Therapy 2 predicts subsequent survivalBlood, 2009
- Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2British Journal of Haematology, 2008
- Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3British Journal of Haematology, 2007
- A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1Blood, 2006
- The molecular classification of multiple myelomaBlood, 2006
- Thalidomide and Hematopoietic-Cell Transplantation for Multiple MyelomaNew England Journal of Medicine, 2006
- International Staging System for Multiple MyelomaJournal of Clinical Oncology, 2005
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958
- Individual Comparisons by Ranking MethodsJournal of Economic Entomology, 1945